This program is designed to generate therapeutic antibodies or proteins against validated drug targets, with the goal of advancing these to pre-clinical development. Leveraging support from our industry partner, Takeda Pharmaceuticals Co., Tri-I TDI will provide resources to discovery and engineer therapeutic antibodies and proteins that will be used for in vitro and in vivo proof-of-concept studies in the laboratory of the principal investigator (PI). Outcomes can include monospecific or bispecific antibodies, antibody-drug conjugates, and protein therapeutics.
Principal Investigators, who are full-time employees of Weill Cornell Medicine, are eligible to apply. Letters of Intent due March 3, 2023.
Log into your VPN to access the application page for more details and application process: https://intranet.tritdi.org/applications/therapeutic-antibodies/.